Matthew Fust is an advisor to life sciences companies, executive teams and investors.
From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Prior to joining ALZA, Matthew was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture).
Matthew serves on the boards of directors of the publicly-traded biotechnology companies Atara Biotherapeutics, Dermira, MacroGenics, Sunesis Pharmaceuticals and Ultragenyx Pharmaceutical.
He holds an undergraduate degree from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.